Forty-seven clinically relevant late-phase programs identify development trajectories for PD-1 and PD-L1 therapies through 2030
47 late-phase programs aim to improve PD-1/PD-L1 cancer therapies
This narrative review analyzes registry-derived clinical trial data to identify future directions for PD-1 and PD-L1 inhibitor therapies. Th…
A new review maps 47 late-phase programs working to overcome limits of PD-1/PD-L1 cancer treatments through 2030.
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
Multi-Omic Biomarkers May Improve Lung Cancer Treatment Predictions
This narrative review explores the integration of chemokine signatures and multi-omic biomarkers to predict immune checkpoint inhibitor resp…
New research suggests that combining multiple biological markers can better predict how lung cancer patients will respond to immunotherapy.
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Systematic review of immune checkpoint inhibitors in cancer efficacy and safety
Immune Checkpoint Inhibitors Show Promise For Cancer Patients With High Tumor Burden
This systematic review synthesizes evidence from 15 randomized trials and cohort studies on immune checkpoint inhibitors in cancer. It finds…
A review of trials suggests immune checkpoint inhibitors work well for some cancer patients but carry risks like skin rashes and organ infla…
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Systematic review examines immune checkpoint inhibitors, innate immunity, and immune-related adverse events in cancer patients
A review suggests innate immunity plays a key role in cancer drug side effects
This systematic review evaluated immune checkpoint inhibitors (ICIs) in patients with cancer, focusing on immune-related adverse events (irA…
Cancer drugs that help fight tumors can also cause serious inflammation, and new research shows the body's first line of defense plays a key…
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.